Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study
Br J Dermatol
.
2022 Oct;187(4):602-603.
doi: 10.1111/bjd.21628.
Epub 2022 Jul 11.
Authors
Fatma Jendoubi
1
,
Jason Shourik
,
Julien Seneschal
,
Francoise Giordano-Labadie
1
,
Nadia Raison-Peyron
,
Aurélie Du-Thanh
,
Florence Tetart
,
Aude Valois
,
Catherine Droitcourt
,
Aude Clément
,
Audrey Nosbaum
,
Marie Noelle Crepy
,
Marie Jachiet
,
Jean David Bouaziz
,
Claire Bernier
,
Angéle Soria
,
Carle Paul
1
,
Sebastien Barbarot
,
Marie Tauber
1
;
GREAT network (Groupe de Recherche sur l’Eczema ATopique of the French Society of Dermatology)
Affiliation
1
Dermatology Department, Toulouse University and CHU (University Hospital), Toulouse, France.
PMID:
35481677
PMCID:
PMC9796038
DOI:
10.1111/bjd.21628
No abstract available
Publication types
Letter
Multicenter Study
MeSH terms
Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Dermatitis, Atopic* / drug therapy
Humans
Retrospective Studies
Substances
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
dupilumab